TD Cowen lowered the firm’s price target on Amwell (AMWL) to $7 from $10 and keeps a Hold rating on the shares. The firm said its 3Q adj. EBITDA beat/raise and reiterating ’26 CF breakeven target are positive for cost reduction priorities.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell price target lowered to $6 from $8 at Stifel
- American Well: Balancing Cost Reductions and Revenue Challenges Amidst Transformation
- Amwell Reports Strong Q3 2025 Financial Performance
- American Well: Hold Rating Amid Revenue Concerns and Strategic Initiatives
- Amwell lowers top-end of FY25 revenue view to $245M-$248M from $245M-$250M